Extension of Time to File SOU

RAPIDVAX

Heat Biologics, Inc.

Request for Extension of Time to File a Statement of Use

PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 90387503
LAW OFFICE ASSIGNED LAW OFFICE 113
MARK SECTION
MARK RAPIDVAX (see, http://uspto.report/TM/90387503/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT RAPIDVAX
OWNER SECTION (current)
NAME Heat Biologics, Inc.
MAILING ADDRESS 801 Capitola Drive, Bay 12
CITY Durham
STATE North Carolina
ZIP/POSTAL CODE 27713
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
OWNER SECTION (proposed)
NAME Heat Biologics, Inc.
MAILING ADDRESS 801 Capitola Drive, Bay 12
CITY Durham
STATE North Carolina
ZIP/POSTAL CODE 27713
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME RACHELLE A. DUBOW, ESQ.
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@morganlewis.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) rachelle.dubow@morganlewis.com; peter.byrne@morganlewis.com; jennifer.kagan@morganlewis.com
CORRESPONDENCE INFORMATION (proposed)
NAME Rachelle A. Dubow, Esq.
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@morganlewis.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) rachelle.dubow@morganlewis.com; peter.byrne@morganlewis.com; jennifer.kagan@morganlewis.com
DOCKET/REFERENCE NUMBER 114358-0002
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations for the treatment or prevention of cancer, immune-related diseases, and infectious diseases
GOODS OR SERVICES KEEP ALL LISTED
INTERNATIONAL CLASS 042
CURRENT IDENTIFICATION Research and development of pharmaceutical products
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 1
ALLOWANCE MAIL DATE 06/15/2021
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 2
SUBTOTAL AMOUNT [EXTENSION FEE] 250
TOTAL AMOUNT 250
SIGNATURE SECTION
SIGNATURE /Jeffrey Wolf/
SIGNATORY'S NAME Jeffrey Wolf
SIGNATORY'S POSITION CEO
DATE SIGNED 12/14/2021
SIGNATORY'S PHONE NUMBER 9192407133
SIGNATURE METHOD Sent to third party for signature
FILING INFORMATION
SUBMIT DATE Tue Dec 14 16:54:42 ET 2021
TEAS STAMP USPTO/ESU-XXX.XXX.XXX.XX-
20211214165442736556-9038
7503-781d28b68a72cbbb7dfb
5d417ba66163f9421e06fb7b3
94864dddc70762ba6f6f6-DA-
54404161-2021121313000948
1703



PTO- 1581
Approved for use through 03/31/2024. OMB 0651-0054
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: RAPIDVAX (see, http://uspto.report/TM/90387503/mark.png)
SERIAL NUMBER: 90387503

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Heat Biologics, Inc., having an address of
      801 Capitola Drive, Bay 12
      Durham, North Carolina 27713
      United States
      Email: XXXX
Proposed: Heat Biologics, Inc., having an address of
      801 Capitola Drive, Bay 12
      Durham, North Carolina 27713
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 06/15/2021.

For International Class 005:
Current identification: Pharmaceutical preparations for the treatment or prevention of cancer, immune-related diseases, and infectious diseases

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


For International Class 042:
Current identification: Research and development of pharmaceutical products

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      RACHELLE A. DUBOW, ESQ.
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; peter.byrne@morganlewis.com; jennifer.kagan@morganlewis.com

Correspondence Information (proposed):
      Rachelle A. Dubow, Esq.
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; peter.byrne@morganlewis.com; jennifer.kagan@morganlewis.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Jeffrey Wolf/      Date Signed: 12/14/2021
Signatory's Name: Jeffrey Wolf
Signatory's Position: CEO
Signatory's Phone: 9192407133
Signature method: Sent to third party for signature

PAYMENT: 90387503
PAYMENT DATE: 12/14/2021

Serial Number: 90387503
Internet Transmission Date: Tue Dec 14 16:54:42 ET 2021
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.XX-202112141654427
36556-90387503-781d28b68a72cbbb7dfb5d417
ba66163f9421e06fb7b394864dddc70762ba6f6f
6-DA-54404161-20211213130009481703




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed